Q4 sales and 2025 guidance exceeded expectations
06/02/25 -"The Q4 sales were ahead of the consensus, though operating profits were somewhat behind the street’s expectations. Also, a better-than-expected 2025 outlook was well received by the markets. ..."
Pages
65
Language
English
Published on
06/02/25
You may also be interested by these reports :
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum
20/08/25
Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...